Last update: Aug. 28, 2020
Minimal risk for breastfeeding and infant.
It is an angiotensin II receptor antagonist with actions similar to those of losartan.
It is indicated in the treatment of hypertension and in heart failure.
Oral administration once or twice a day.
Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) explain the negligible passage into milk observed (Coberger 2019).
The plasma levels of infants whose mothers take candesartan were indetectable (Coberger 2019).
Its low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM